COMPANY

Alzheon

HQ: Framingham, MA source · alzheon.com ↗ · New England

Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer's disease and a discovery platform of small molecules for neurodegenerative disorders. From company website Source · checked 2026-10-19

Sources for this description (1)

Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer's disease and a discovery platform of small molecules for neurodegenerative disorders.
- “Founded in 2013 by Martin Tolar, MD, PhD, Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders.” https://alzheon.com/people/about-us/ (2026-10-19)

Disease: alzheimer’s disease

Modality: small molecule

Product: ALZ-801

Keywords: small molecules neurodegenerative Alzheimer Early Alzheimer's Disease Alzheimer Disease Experimental: ALZ-801 ALZ-507

Location: Framingham, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)7NIH grants

Funding and NIH signals

SEC Form D raise Raised $78.8M (Form D filed Sep 10, 2026). SEC Form D 0001582636-26-000002 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · SEC Form D 0001582636-26-000002
  Name of Issuer: ALZHEON, INC.; CIK: 1582636; Address: Framingham, MA; Submission type: D; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-08-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 499999999; Total Amount Sold: 78797184; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series E · $100M · announced Jun 12, 2024 Company release ↗
Source quote
- Jun 12, 2024 · Company release ↗
  “Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease”

Raises announced in these releases: $100M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Mar 9, 2026 Trial start Phase 1: Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults source ↗
Jun 12, 2024 Raise Series E · $100M source ↗
Apr 2, 2024 Trial start 3: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects source ↗
May 19, 2021 Trial start Phase 3: An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects source ↗
Sep 30, 2020 Trial start Phase 2: Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease source ↗
Sep 26, 2015 Trial start Phase 1: Multiple Ascending Dose Study of ALZ-801 source ↗
Sep 16, 2015 Trial start Phase 1: Single Dose Study of ALZ-801 Prototype Tablets source ↗

Upcoming milestones

Oct 28, 2026 (ESTIMATED) · Phase 1 · Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults · NCT07824271

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT04770220	An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects	Phase 3	Completed	May 19, 2021	May 29, 2024 (actual)
NCT07824271	Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults	Phase 1	Recruiting	Mar 9, 2026	Oct 28, 2026 (estimated)
NCT06304883	Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects	3	Terminated	Apr 2, 2024	Mar 11, 2026 (actual)
NCT04693520	Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease	Phase 2	Completed	Sep 30, 2020	Jun 20, 2023 (actual)
NCT04585347	Single Dose Study of ALZ-801 Prototype Tablets	Phase 1	Completed	Sep 16, 2015	Nov 13, 2015 (actual)
NCT04157712	Multiple Ascending Dose Study of ALZ-801	Phase 1	Completed	Sep 26, 2015	Jul 4, 2016 (actual)

NIH awards 7

Annual award amounts. Total $51.2M.

Jul 10, 2024 NIH award 5R01AG065253-05 FY2024: $2,265,244 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Control source ↗
Jul 14, 2023 NIH award 3R01AG065253-04S1 FY2023: $425,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Control source ↗
Jun 14, 2023 NIH award 5R01AG065253-04 FY2023: $6,500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Control source ↗
Jul 8, 2022 NIH award 3R01AG065253-03S1 FY2022: $3,500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Contr source ↗
Jun 24, 2022 NIH award 5R01AG065253-03 FY2022: $11,000,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Contro source ↗
Jun 16, 2021 NIH award 5R01AG065253-02 FY2021: $12,500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Contro source ↗
Aug 11, 2020 NIH award 1R01AG065253-01A1 FY2020: $15,000,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI ABUSHAKRA, SUSAN; recipient as written: ALZHEON, INC., Framingham, MA. Randomized, Double-Blind, Placebo-Cont source ↗